Search Results
Results 401 - 450 of 1101
< 4 5 6 7 8 9 10 11 12 13 14 >
White HD - - 1997
The direct thrombin inhibitor, hirudin, was tested in two trials. The TIMI 9B trial randomized patients receiving thrombolytic therapy for acute myocardial infarction to receive hirudin or heparin. The GUSTO IIB trial randomized patients with or without electrocardiographic ST-segment elevation (i.e. thrombolytic- and non-thrombolytic-eligible patients). In the combined trials at ...
Stringer K A - - 1997
Exogenous plasminogen activators (PAs), such as streptokinase (SK) and tissue plasminogen activator (tPA), have been shown to significantly improve the mortality of patients with acute myocardial infarction. However, reperfusion of the myocardium is associated with neutrophil activation and infiltration into the infarct region. Plasminogen activators influence neutrophil function in vitro, ...
Smith JJ - - 1997
Randomized trials of reperfusion therapy completed over the past decade have engendered the open-artery hypothesis. Collectively, patients with patent infarct-related arteries have fewer complications of their myocardial infarction, salutary effects on ventricular remodeling, and better survival. Thrombolytic therapy has been widely regarded as the most appropriate initial therapy for acute ...
Aversano T - - 1997
There are more than 600,000 acute myocardial infarctions (AMIs) in the United States each year, with direct medical costs exceeding $16 billion per year. Two treatment strategies are available for AMI today: medical therapy, including thrombolytic therapy, and primary angioplasty. Despite provocative preliminary data suggesting primary angioplasty results in lower ...
Johnson TL - - 1997
Early clinical trials of thrombolytic therapy in the setting of acute myocardial infarction (AMI) demonstrated that early angiographic reperfusion correlated with improved survival. This supported the open-artery hypothesis that early reperfusion decreases infarct size, improves left ventricular function, and improves survival. Two subsequent comparative thrombolytic trials showed no difference in ...
Conrad A R - - 1997
Cerebrovascular accidents are one of the most serious causes of morbidity in patients sustaining an acute myocardial infarction. In patients who do not receive thrombolytic therapy, the most common form of stroke is thromboembolic, occurring in up to 2.4% of patients, predominantly in those sustaining large anterior infarctions. In patients ...
Alexander JH - - 1997
A direct relationship exists between infarct artery patency and survival in patients with acute myocardial infarction. Currently available thrombolytic regimens produce 90 minute patency rates on the order of 80%. Preliminary trials suggest that adjunctive anti-platelet therapy with glycoprotein IIb/IIIa inhibitors, in conjunction with thrombolytic therapy, may significantly improve 90 ...
Woodfield S L - - 1997
OBJECTIVES: This study sought to 1) determine the effect of gender on early and late infarct-related artery patency and reocclusion after thrombolytic therapy for acute myocardial infarction; 2) examine the effect of gender on left ventricular function in response to injury/reperfusion; and 3) assess the independent contribution of gender to ...
Ellis CJ - - 1997
Central to many of the major advances seen in the treatment of acute myocardial infarction over the last 15 years has been the concept that reperfusion by thrombolytic therapy, by producing early patency of an infarct-related artery, salvages myocardium and preserves left ventricular function. Large clinical trials have confirmed the ...
Srinivasan G - - 1997
Treatment with thrombolytic agents such as streptokinase or tissue plasminogen activator (TPA) is an accepted standard for the treatment of patients with acute myocardial infarction (MI). A devastating sequel of thrombolytic therapy may be the development of a hemorrhagic complication, particularly intracranial bleeding, which, although rare, is usually associated with ...
Shen L - - 1997
OBJECTIVE: To investigate the effects of thrombolytic therapy on recanalization in different starting time of treatment after acute myocardial infarction. METHODS: 172 cases with intravenous thrombolytic agents were divided into 4 groups: < or = 2 hours, > 2-4 hours, > 4-6 hours and > 6-12 hours, according to the ...
Smalling R W - - 1996
The initial work on thrombolytic therapy for acute myocardial infarction (AMI) focused on intracoronary administration of streptokinase. Continuing research has given rise to the development of both second- and third-generation agents and consequent refinements in thrombolytic regimens. Intravenous recombinant tissue plasminogen activator (t-PA, or alteplase) proved superior to both intracoronary ...
Bode C - - 1996
Thrombolytic therapy has been shown to reduce mortality and morbidity after acute myocardial infarction. Therapeutic benefit seems to be directly correlated with completeness of reperfusion (Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow) of the infarct-related coronary artery, as well as the timeliness of reperfusion. To determine which regimen of ...
Pepine C J - - 1996
In the era of multiple new therapies (e.g., aspirin, beta blockers, thrombolysis, angiotensin-converting enzyme inhibitors, etc.) with the potential to improve outcome, the utility of traditional methods for predicting risk for adverse outcome after acute myocardial infarction (MI) is being reevaluated. Recent data suggest that heart failure, male gender, older ...
Weaver W D - - 1996
Optimal thrombolytic therapy in acute myocardial infarction must aim to achieve early and complete reperfusion of the infarct related coronary artery. Establishment of normal coronary flow (Thrombolysis in Myocardial Infarction [TIMI] grade 3) is the key correlate of improved survival. Three large-scale clinical trials, the Reteplase Angiographic Phase II International ...
Chen C K - - 1996
BACKGROUND: Reduced heart rate variability after acute myocardial infarction is an important risk stratification factor for mortality and life threatening ventricular arrhythmias. In recent years, thrombolytic therapy has revolutionized the therapy of acute myocardial infarction. However, there is little information about the mechanism of the beneficial effect of thrombolysis on ...
Dakik H A - - 1996
BACKGROUND: Although myocardial perfusion scintigraphy is of proven value in the risk stratification of patients with a recent myocardial infarction who receive conventional therapy, its value in patients undergoing thrombolytic therapy remains controversial. METHODS AND RESULTS: Seventy-one patients who received thrombolytic therapy for acute myocardial infarction had exercise 201Tl tomography ...
Jung J - - 1996
The intraindividual changes of ventricular late potentials and their possible determinants were examined prospectively in 88 consecutive patients (male: 75; mean age: 58 +/- 9 years) after thrombolytic therapy for acute myocardial infarction. Late potential analysis was performed 4 weeks and 12 months after acute myocardial infarction. At the same ...
Markel K N - - 1996
The objective of this study was to implement a system of continuous quality improvement to reduce delays in the administration of thrombolytic therapy for patients with acute myocardial infarction in the emergency department (ED). The setting was a community hospital ED with an annual census of approximately 40,000 patients. The ...
Mair F S - - 1996
Although thrombolytic therapy is used in a variety of settings, it has gained the most prominence in the treatment of myocardial infarction. The effectiveness of thrombolytic agents in reducing mortality in patients who present with myocardial infarction has been clearly demonstrated by large-scale studies. Unfortunately, only a minority of patients ...
Kono T - - 1996
OBJECTIVES: Using a prospective, randomized design, we tested our hypothesis that the augmentation of diastolic pressure by intraaortic balloon counterpulsation (IABP) would improve the late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy. BACKGROUND: Rescue angioplasty is often performed in patients in whom thrombolysis ...
Druwé P M - - 1996
A patient with an acute myocardial infarction had to be resuscitated due to recurring ventricular fibrillation. After stabilisation, she received thrombolytic treatment with anistreplase. Fourteen hours later, clinical signs of hemoperitoneum developed and the diagnosis of liver rupture was made. After abdominal surgery and coronary revascularisation, the subsequent clinical course ...
Noble S - - 1996
Reteplase (BM 06.022; r-PA) is a recombinant peptide which consists of the kringle 2 and protease domains of human tissue-type plasminogen activator. It has been developed as a thrombolytic treatment for acute myocardial infarction (AMI). The half-life of reteplase allows administration as a double-bolus injection (second injection given 30 minutes ...
Cairns J A - - 1996
The postulate that thrombotic coronary occlusion was the underlying pathophysiologic event in the acute coronary ischemic syndromes was developed over the years 1912-60. This concept prompted the development of anticoagulant and thrombolytic therapies and the use of acetylsalicylic acid in such patients. A central role for coronary thrombus came to ...
Godfried S L - - 1996
Antithrombotic and thrombolytic therapies confer clear net benefits in the treatment of acute myocardial infarction. Antithrombotic therapy with aspirin yields conclusive reductions in vascular mortality as well as reinfarction and stroke, and should be administered to all patients with suspected acute myocardial infarction. There is presently no clear evidence of ...
Scharfstein J S - - 1996
Thrombin activity is increased in the setting of acute myocardial infarction (AMI) and has been shown to increase further after the administration of thrombolytic therapy for acute infarction. This increase in thrombin activity may play an important role in the 15% to 25% rate of failure to achieve initial reperfusion ...
Brouwer M A - - 1996
The Myocardial Infarction Triage and Intervention Trial of prehospital versus hospital administration of thrombolytic therapy markedly reduced hospital treatment times, but the 2 groups had similar outcomes. However, patients treated < 70 minutes from symptom onset had better short-term outcomes. The purpose of this study was to determine the long-term ...
Bode C - - 1996
BACKGROUND: The therapeutic benefit of thrombolytic therapy has been shown to correlate directly with completeness (TIMI grade 3 flow) and speed of reperfusion of the infarct-related coronary artery. The purpose of the RAPID II study was to determine whether a double-bolus regimen of reteplase, a recently developed deletion mutant of ...
Amsterdam E A - - 1996
Although the ability of a thrombolytic agent to lyse a clot has been recognized for over 50 years, it was not until recently that this form of therapy was used to treat acute myocardial infarction. The need for rapid diagnosis and timely treatment to provide optimum outcomes and prognosis is ...
Armstrong P W - - 1996
Four thrombolytic comparative trials without a placebo arm have each been conducted in populations of more than 1000 patients: GISSI-2 International, ISIS-3, GUSTO, and INJECT. The treatment strategy associated with use of intravenous heparin and the accelerated regimen of tissue plasminogen activator (t-PA) accounts for the differences between the results ...
Topol E J - - 1996
Early, complete, and sustained myocardial reperfusion is the principal goal of thrombolytic therapy. Unfortunately, the majority of patients treated today experience substantial delay before the initiation of thrombolytic therapy and, once treated, demonstrate suboptimal results of coronary thrombolysis. This is attributable, in part, to the underlying thrombus, which is platelet ...
Vahanian A - - 1996
Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early ...
Bode C - - 1996
The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large efforts have been undertaken to develop more effective and safer thrombolytic agents. In addition, ...
Weaver W D - - 1996
Two angiographic trials, RAPID 1 in 606 patients and RAPID 2 in 324 patients, assessed angiographic patency after acute myocardial infarction following treatment with reteplase and alteplase. RAPID 1 evaluated three bolus regimens of reteplase in comparison with a 3 h infusion of alteplase. RAPID 2 compared the 10 MU ...
Stringer K A - - 1996
The number of thrombolytic drugs for the management of acute myocardial infarction is rapidly expanding. New agents, some of which are biochemically modified versions of currently available thrombolytics, will soon arrive in the marketplace. The pharmacologic differences of the new drugs are the basis for clinical differences such as enhanced ...
Califf R M - - 1996
Substantial progress has been made toward understanding the pathophysiological processes that lead to acute myocardial infarction. Research has shown that the mechanism of infarction is the rupture of an atherosclerotic plaque with a subsequent thrombogenic response from exposed subendothelial tissue, leading to additional or complete obstruction of the vessel. Myocardial ...
Schaer G L - - 1996
BACKGROUND: RheothRx (poloxamer 188) is a surfactant with hemorheological and antithrombotic properties that reduces myocardial reperfusion injury in animal models of myocardial infarction. The purpose of the present study was to evaluate the safety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy for acute myocardial ...
Shechter M - - 1996
Only one third of hospitalized patients with acute myocardial infarction receive thrombolytic therapy despite its proven benefits on outcomes. Elderly patients, for example, have a greater risk of death after myocardial infarction, but studies demonstrate that thrombolytic therapy is less likely to be used in older patients. Intravenous magnesium supplementation, ...
Glogar D - - 1996
The management of acute myocardial infarction initially focused on treatment and/or prevention of complications. In the prethrombolytic era, therapeutic regimens mainly comprised the use of antianginal and antiarrhythmic drugs. The development of semi-invasive hemodynamically guided treatment concepts led to remarkable improvement in clinical outcome. After the introduction of the "wave-front ...
Jacobs I G - - 1996
BACKGROUND: While use of thrombolytic therapy in the management of acute myocardial infarction has become accepted practice in major teaching hospitals, its use in peripheral metropolitan hospitals has not been well accepted. AIM: To evaluate the use of thrombolytic therapy in the management of acute myocardial infarction in the Emergency ...
Rosamond W D - - 1996
Between 1990 and 1993, patient selection and relative effectiveness of thrombolytic agents were issues for clinical trials of thrombolytic therapy, particularly the Third International Study of Infarct Survival (ISIS-3) and the Second Gruppo Italiano per Lo Studio della Streptochinasi nell'Infarto Miocardico trials. The purpose of this report is to document ...
Gutman M B - - 1996
Patients with acute myocardial infarct (AMI) need rapid diagnosis and prompt initiation of thrombolytic therapy. Patients with suspected cardiac ischemia must receive a coordinated team response by the emergency room staff including rapid electrocardiographic analysis and a quick but thorough history and physical examination to diagnose AMI. Thrombolysis and adjunct ...
Quigley R L - - 1996
Thrombolytic agents are used to restore coronary artery perfusion and limit the size of a myocardial infarction. The systemic effects of these drugs, streptokinase (SK), urokinase (UK), and recombinant tissue plasminogen activator (rtPA), have been studied extensively. Although their effects on rheology and late myocardial performance have been well-documented to ...
Ho Y L - - 1996
A dilemma must be faced when deciding whether or not to use thrombolytic therapy in patients with acute myocardial infarction and circulating antiphospholipid antibody. This report is about a patient whose infarct-related coronary artery was successfully revascularized by recombinant tissue plasminogen activator without any major bleeding complications. The nature of ...
Rutherford J D - - 1996
Most patients with acute myocardial infarction do not receive or are ineligible for thrombolytic therapy, and thus their prognosis is worse than that of the populations studied in the major, randomized, lytic therapy trials. We need to devise a cost-effective strategy with which to appropriately stratify these patients. Simple, easily ...
French J K - - 1996
OBJECTIVES: To determine the proportion of patients presenting with acute myocardial infarction who are eligible for thrombolytic therapy. DESIGN: Cohort follow up study. SETTING: The four coronary care units in Auckland, New Zealand. SUBJECTS: All 3014 patients presenting to the units with suspected myocardial infarction in 1993. MAIN OUTCOME MEASURES: ...
Leone A - - 1996
One hundred and sixty-eight out of 296 patients who died of acute myocardial infarction (AMI) in the Coronary Care Unit were studied to assess the cause of death. Twenty-two of them had received thrombolytic therapy. The mean age of these patients was 64.3 +/- 18.2 years. One hundred and eight ...
de Chillou C - - 1996
OBJECTIVES: This study sought to determine whether the reopening of the infarct-related vessel is related to clinical characteristics or cardiovascular risk factors, or both. BACKGROUND: In acute myocardial infarction, thrombolytic therapy reduces mortality by restoring the patency of the infarct-related vessel. However, despite the use of thrombolytic agents, the infarct-related ...
Beauregard L A - - 1996
Signal averaging has been performed to evaluate late potentials following infarction and the administration of thrombolytic therapy. Most studies have recorded signal-averaged electrocardiograms (SAECGs) at least 12 hours after the onset of the infarction. In this study, SAECGs were recorded before thrombolytic therapy and serially over 7-10 days following infarction ...
Ohlin A K - - 1996
Thrombomodulin (TM) is an integral endothelial cell membrane protein that functions as a cofactor for thrombin mediated activation of protein C. The anticoagulant functions of the protein C system are important in contributing to a hemostatic balance and prevention of thromboembolic disease. It has been suggested that impaired TM cofactor ...
< 4 5 6 7 8 9 10 11 12 13 14 >